Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma
| Autor: | Jolique A van Ipenburg, Adrian Daly, Esther Donga, Aart-Jan van der Lely, Kay J Pieterman, Leo J. Hofland, Eva C Coopmans, Albert Beckers, Sebastian J C M M Neggers, Sebastiaan W F van Meyel |
|---|---|
| Přispěvatelé: | Internal Medicine, Medical Informatics, Pathology |
| Rok vydání: | 2019 |
| Předmět: |
Adenoma
medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Tumor Cell Necrosis 030209 endocrinology & metabolism 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Dopamine Internal medicine medicine Humans Neoplasm Invasiveness Pituitary Neoplasms Prolactinoma Temozolomide business.industry General Medicine Middle Aged medicine.disease Hormones Pasireotide Tumor Burden Radiation therapy Treatment Outcome Somatostatin chemistry Drug Resistance Neoplasm 030220 oncology & carcinogenesis Dopamine Agonists Cancer research Female Neurosurgery business medicine.drug |
| Zdroj: | European Journal of Endocrinology, 181(2), K21-K27. Bioscientifica Ltd |
| ISSN: | 1479-683X 0804-4643 |
| DOI: | 10.1530/eje-19-0279 |
| Popis: | Prolactinomas are the most commonly encountered pituitary adenomas in the clinical setting. While most can be controlled by dopamine agonists, a subset of prolactinomas are dopamine-resistant and very aggressive. In such tumors, the treatment of choice is neurosurgery and radiotherapy, with or without temozolomide. Here, we report a patient with an highly aggressive, dopamine-resistant prolactinoma, who only achieved biochemical and tumor control during pasireotide long-acting release (PAS-LAR) therapy, a second-generation somatostatin receptor ligand (SRL). Interestingly, cystic degeneration, tumor cell necrosis or both was observed after PAS-LAR administration suggesting an antitumor effect. This case shows that PAS-LAR therapy holds clinical potential in selective aggressive, dopamine-resistant prolactinomas that express somatostatin (SST) receptor subtype 5 and appears to be a potential new treatment option before starting temozolomide. In addition, PAS-LAR therapy may induce cystic degeneration, tumor cell necrosis or both in prolactinomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|